MBX Biosciences (MBX) stock
MBX's Quality Score rose 2 points on Tue, Nov 10, to 4. Its week-by-week trend turned up (3 chart checks started).
Follow MBX's trial news. Pro members can get an alert when MBX Biosciences files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on MBX
| Holding it back | 42.0% more shares than a year ago |
| Latest filing | 8-K, Nov 9 |
MBX in the news
ReportLast night: a loss of $1.29 a share. Past reports ›
What's next
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
2 more dates ahead: conferences, for Pro members.
MBX catalysts
After its last 4 reports it closed +4.6% on average, higher 2 of 4 times.
What's next for MBX, and how long its cash lasts
Next step the company has named
Cash runway
The company says its cash lasts into 2029 (8-K, Nov 9).
Dilution on the horizon
- Shelf registration (S-3ASR, filed Mar 12, 2026)
- At-the-market share sales program (S-3ASR, filed Mar 12, 2026)
Insiders
Chief Medical Officer Salomon Azoulay sold 373 shares on Nov 4. 5 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why MBX scores 4
Below Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
- +5Chart checks 5 of 14 firing right now, one point each
- +2Long-term trend above a rising 200-day average
- Run-up adds
- Profit subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
How MBX ranks in Biotech
MBX is #88 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 88 |
Share count against a year before: MBX +42%, VKTX +5.1%, WVE +22%, GPCR +25%.
When does MBX report earnings, and what happens after?
Expected to report Thu Mar 18, after the close (in 128 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What MBX reported on Nov 9, 2026
The quarter
A loss of $1.29 a share, from $0.63.
“The increase of $12.7 million was driven by an increase in start-up costs related to the canvuparatide Phase 3 clinical trial which was initiated in the third quarter of 2026, ongoing conduct of the canvuparatide Phase 2 open-label extension clinical trial, ongoing conduct of the MBX 4291 Phase 1 clinical trial and timing of preclinical and IND-enabling activities related to MBX 5765 and MBX 6180.”
Where the sales came from
MBX's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The increase of $29.6 million was driven by higher personnel-related costs, including $20.8 million of stock-based compensation expense related to the modification of awards for the Company’s former chief executive officer, and other higher personnel-related costs resulting from continued expansion of both the Company’s executive leadership team and general infrastructure to support growth in the Company’s operations.”
From its results filing (SEC filing · Nov 9)
The numbers
- $2.3B
- today
- -$99.3M
- last 12 months
Close after the report, last 3
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 9, 2026 | -4.7% | +4.2% | not yet |
| Aug 6, 2026 | -1.9% | -0.6% | -0.8% |
| May 7, 2026 | +0.7% | +18.0% | +1.9% |
MBX has 5 of 14 chart checks firing
MBX RSI today: 55.0, above its 50-day and 200-day averages
RSI 55.0, MACD above signal, above both averages. Not scored.
The deep dive on MBX
- What it does and how it makes money
- Where it standsSEC filing · Sep 25, 2025
- Who holds and trades it
- Against its closest peers
MBX insider trades
One insider sold $44K across 2 filings in the last 6 months. No open-market buys on record. The newest:
MBX's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold MBX?
In ETFs: MBX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About MBX Biosciences
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn MBX's score around: 7 things
- 8 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does MBX's Quality Score say?
MBX scores 4 today, which Breakaway calls Below Average. It is #88 of 281 in Biotech by Quality Score, with 5 of 14 chart checks firing. Shares: 42.0% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is MBX's Quality Score?
MBX scores 4 today, which Breakaway calls Below Average (0 to 5). That is #88 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MBX's 4.
Are insiders buying MBX?
One insider sold $44K across 2 filings in the last 6 months. No open-market buys on record. The newest is Salomon Azoulay, Chief Medical Officer, who sold $20K on Nov 4. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.